Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motion Delos
NCT06138613Phase 3Active, not recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Feb 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tradipitant in motion sickness, sponsored by Vanda Pharmaceuticals Inc.. Started Feb 2023; status: active, not recruiting.
02
Drugs
tradipitant
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT06138613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138613.